<?xml version="1.0" encoding="UTF-8"?>
<p>Ad5-nCoV is the first COVID-19 vaccine in a clinical trial in China.
 <sup>
  <xref rid="cit0038" ref-type="bibr">38</xref>
 </sup> The vaccine developed by CanSinoBIOâ€™s adenovirus-based viral vector vaccine technology platform. In the human trial of the vaccine, it is found safe and induces a rapid immune response. The AZD1222 CoV vaccine, formerly known as ChAdOx1 nCoV-19, developed from ChAdOx1 virus. The ChAdOx1 vaccine is in clinical trials to prevent infection of SARS-CoV-2. AstraZeneca Plc announced it selected Emergent BioSolutions to produce the 300 million doses of the COVID-19 vaccine candidate. The oxford- AstraZeneca in the phase I/II trial tolerated and generated strong immune responses in all the participants in the United Kingdom. The vaccine has entred in its final trial in Brazil along with studies going on in the United Kingdom and South Africa. Similarly Pfizer also trigerred strong T-cell response in phase I/II and has entered the pase III trial. The Sinovac Biotech Ltd. developed the CoronaVac SARS-CoV-2 vaccine based on an inactivated virus. Sinovac Biotech got approval from Chinese authorities to conduct both the phase-I and phase-II human clinical trials for CoronaVac in China. DNA vaccine INO-4800 designed to prevent SARS-CoV-2 from infecting humans is under phase-I/II clinical trial by INOVIO and Seoul National University Hospital and is expected to be available by November 2020.
 <sup>
  <xref rid="cit0039" ref-type="bibr">39</xref>
 </sup>
</p>
